Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
BGI GENOMICS CO., LTD. has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners across 2 distinct art units. This concentration in 2 art units indicates a focused technological scope despite the involvement of 4 distinct examiners. The Biotechnology & Pharmaceuticals area is the primary field for all 5 pending office actions currently under review.
MONTANARI, DAVID A is the busiest examiner, managing 2 pending office actions. The other pending office actions are distributed among the remaining examiners. Because the portfolio is limited to 2 distinct art units, there may be significant technical overlap between the applications. Practitioners should monitor the 4 distinct examiners for potential differences in how they apply the rules within these units to ensure a cohesive strategy for the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 2 | 64.8% | +49.0% |
| MAHADEVAN, JANAKI ANANTH | 1 | 0.0% | +0.0% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17413493 | BIOCHIP, METHOD OF PREPARATION AND USE THEREOF | CHO, DAVID H | 79d |
| 18284054 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | MAHADEVAN, JANAKI ANANTH | — |
| 18033037 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BERRY, LAYLA D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17413493 | BIOCHIP, METHOD OF PREPARATION AND USE THEREOF | CHO, DAVID H | 79d |
| 18036578 | Media and methods for establishing and maintaining early embryo-like cells | MONTANARI, DAVID A | — |
| 18036588 | Media and methods for establishing and maintaining early embryo-like cells | MONTANARI, DAVID A | — |
| Art Unit | Apps |
|---|---|
| 1693 | 3 |
| 1632 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284054 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | MAHADEVAN, JANAKI ANANTH | 1693 | §101§112 | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18036578 | Media and methods for establishing and maintaining early embryo-like cells | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | — | Pending | May 11, 2023 |
| 18036588 | Media and methods for establishing and maintaining early embryo-like cells | MONTANARI, DAVID A | 1632 | §112 | Final Rejection | — | Pending | May 11, 2023 |
| 18033037 | MODIFIED NUCLEOSIDE OR NUCLEOTIDE | BERRY, LAYLA D | 1693 | §101§102Other | Non-Final OA | — | Pending | Apr 20, 2023 |
| 17413493 | BIOCHIP, METHOD OF PREPARATION AND USE THEREOF | CHO, DAVID H | 1693 | §103§112 | Final Rejection | 79d | Pending | Jun 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBGI GENOMICS CO., LTD. has 5 pending office actions as of October 2026, spread across 2 art units and 4 examiners.
David A Montanari has the most, with 2 of BGI GENOMICS CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
